Peptifact

FDA-Approved Peptides: The Full List, Read From Drugs@FDA, With What Is Still on the Market

FDA publishes no list of approved peptides, so we built one from its own approvals database: 43 peptide active ingredients of 40 amino acids or fewer, from corticotropin in 1952 to elamipretide in 2025, with application numbers, first approval dates and whether anything is still marketed. Six have nothing left on the market. The popular clinic and research peptides — BPC-157, TB-500, CJC-1295, ipamorelin, MOTS-c — are not on it.

Robert F · Edited by Caroline S · Published 2026-10-06 · Updated 2026-10-20

Illustration: A clean, partially disassembled laboratory pipette and a glass vial with powder on a cool grey lab bench.
Illustration

FDA does not publish a list of approved peptides. Its approvals database, Drugs@FDA, lists drugs by product and application, not by chemical class, so "which peptides are approved" has no official answer. This page builds one, states exactly how, and keeps the result reproducible.

What it means for a compound to be approved, compounded or sold as research material is explained on our peptide therapy page, and what "research use only" does and does not mean is on our research-use-only page. Which of these approved products a health plan will pay for, and the federal exclusions that decide it, is on our peptide insurance coverage page.

How this list was built

What counts as a peptide here. FDA's own line: under 21 CFR 600.3(h)(6), a protein is "any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size." So a peptide, for this census, is a defined chain of 40 amino acids or fewer. That matters because on 23 March 2020 FDA moved approved proteins from drug applications to biologics licences, and its transition notice states the change "does not affect 'peptides' (i.e., polymers composed of 40 or fewer amino acids)."

What is left out, and why. Insulin and other proteins (over 40 amino acids). Antibiotics and immunosuppressants built from amino acids, such as vancomycin, daptomycin and cyclosporine, which nobody asks about as "peptides". Small modified di- and tripeptide molecules such as bortezomib. These are editorial choices; a different boundary gives a different count, which is why published totals disagree.

Where the data came from. Each product was looked up by brand and by active ingredient in Drugs@FDA through openFDA's drugsfda endpoint (data last updated 2026-10-02), read on 2026-10-06. The date given is the earliest approval among the applications listed for that ingredient's reference brand — not always the first approval of the molecule anywhere. "Marketed" means at least one product under that ingredient is listed with a prescription marketing status; "discontinued" means none is.

The census: 43 approved peptide active ingredients

# Active ingredient Reference brand(s) Application First approval listed Status 2026-10-06
1 Corticotropin Acthar Gel; Purified Cortrophin Gel NDA 008372 1952-04-29 Marketed
2 Glucagon Glucagon (Lilly, discontinued); Baqsimi (nasal); Gvoke NDA 012122 1960-11-14 Marketed
3 Cosyntropin Cortrosyn NDA 016750 1970-04-22 Marketed
4 Desmopressin DDAVP; Stimate and Nocdurna (both discontinued) NDA 017922 1978-02-21 Marketed
5 Oxytocin Pitocin NDA 018261 1980-11-19 Marketed
6 Gonadorelin Factrel NDA 018123 1982-09-30 Discontinued
7 Calcitonin salmon Miacalcin NDA 017808 1986-07-03 Marketed (nasal form discontinued)
8 Octreotide Sandostatin; Mycapssa (oral, 2020) NDA 019667 1988-10-21 Marketed
9 Leuprolide Lupron Depot NDA 019732 1989-01-26 Marketed
10 Goserelin Zoladex NDA 019726 1989-12-29 Marketed
11 Sermorelin GEREF NDA 019863 1990-12-28 Discontinued
12 Histrelin Supprelin (discontinued); Supprelin LA (NDA 022058); Vantas (discontinued) NDA 019836 1991-12-24 Marketed
13 Eptifibatide Integrilin (discontinued) NDA 020718 1998-05-18 Marketed as generics (8)
14 Ganirelix Ganirelix acetate NDA 021057 1999-07-29 Marketed
15 Triptorelin Trelstar NDA 020715 2000-06-15 Marketed
16 Cetrorelix Cetrotide NDA 021197 2000-08-11 Marketed
17 Bivalirudin Angiomax NDA 020873 2000-12-15 Marketed
18 Nesiritide Natrecor NDA 020920 2001-08-10 Discontinued
19 Teriparatide Forteo NDA 021318 2002-11-26 Marketed
20 Enfuvirtide Fuzeon NDA 021481 2003-03-13 Discontinued
21 Secretin (synthetic human) ChiRhoStim NDA 021256 2004-04-09 Marketed
22 Ziconotide Prialt NDA 021060 2004-12-28 Marketed
23 Pramlintide Symlin NDA 021332 2005-03-16 Discontinued
24 Exenatide Byetta; Bydureon (discontinued) NDA 021773 2005-04-28 Marketed (Byetta, NDA 021919)
25 Lanreotide Somatuline Depot NDA 022074 2007-08-30 Marketed
26 Degarelix Firmagon NDA 022201 2008-12-24 Marketed
27 Liraglutide Victoza; Saxenda NDA 022341 2010-01-25 Marketed
28 Icatibant Firazyr NDA 022150 2011-08-25 Marketed
29 Linaclotide Linzess NDA 202811 2012-08-30 Marketed
30 Pasireotide Signifor NDA 200677 2012-12-14 Marketed
31 Teduglutide Gattex NDA 203441 2012-12-21 Marketed
32 Vasopressin Vasostrict NDA 204485 2014-04-17 Marketed
33 Plecanatide Trulance NDA 208745 2017-01-19 Marketed
34 Abaloparatide Tymlos NDA 208743 2017-04-28 Marketed
35 Semaglutide Ozempic; Rybelsus; Wegovy (incl. tablets, 2025-12-22) NDA 209637 2017-12-05 Marketed
36 Bremelanotide Vyleesi NDA 210557 2019-06-21 Marketed
37 Afamelanotide Scenesse (implant) NDA 210797 2019-10-08 Marketed
38 Setmelanotide Imcivree NDA 213793 2020-11-25 Marketed
39 Dasiglucagon Zegalogue NDA 214231 2021-03-22 Discontinued
40 Difelikefalin Korsuva NDA 214916 2021-08-23 Marketed
41 Vosoritide Voxzogo NDA 214938 2021-11-19 Marketed
42 Tirzepatide Mounjaro; Zepbound NDA 215866 2022-05-13 Marketed
43 Elamipretide Forzinity NDA 215244 2025-09-19 Marketed

Vasopressin's date is that of Vasostrict, the brand application listed today; the hormone itself was in medical use long before 2014, and the same is true of oxytocin and glucagon. Why vasopressin treats shock while its analogue desmopressin (row 4) treats diabetes insipidus is laid out in how desmopressin and vasopressin differ. The Vasostrict label's adverse-reaction list, which carries no percentages, is read in what the vasopressin label lists and what trials counted. Two of the marketed products have dated pages of their own on price and label risk: what Linzess costs and Lupron Depot side effects. Teduglutide (row 31), the short-bowel-syndrome drug sold as Gattex, is priced from Medicaid and Medicare spending files on Gattex cost.

Counted: 43 ingredients · 37 with a marketed product · 6 with none.

What "discontinued" does and does not mean

A discontinued listing means no product under that application is being marketed. It is not a safety finding. For sermorelin, FDA's database carries a note that GEREF "was not discontinued or withdrawn for safety or effectiveness reasons" — a determination that, under the compounding rules, allows a pharmacy to compound it now. That is the whole reason a drug with no marketed product appears on clinic menus. The full sermorelin record — label, trial doses, clinic listings — is on our page on sermorelin dosing, and what its trials measured is on our sermorelin results page.

The edge cases readers ask about

Name What the record shows
Tesamorelin Approved as EGRIFTA (first 2010-11-10). At 44 amino acids it is a protein under FDA's definition, so its application now carries a biologics number (BLA 022505) and it is not in the 43. Labelled for excess abdominal fat in adults with HIV and lipodystrophy; "not indicated for weight loss management". See what the tesamorelin trials measured.
Mecasermin (IGF-1) Approved as Increlex (BLA 021839). At 70 amino acids it is a protein, not a peptide, by the same rule.
PT-141 Approved under its generic name, bremelanotide (Vyleesi, 2019).
SS-31 Approved under its generic name, elamipretide (Forzinity), on 2025-09-19 — the most recent peptide in the census.
Melanotan Afamelanotide (a melanotan I analogue) is approved as an implant, Scenesse. Melanotan II is not approved.
Gonadorelin The human product, Factrel, is discontinued.

None of these has an approved application in Drugs@FDA. Each is named on FDA's page of bulk drug substances that may present significant safety risks in compounding (content current as of 2026-04-22), usually for possible immunogenicity, peptide-related impurities and little or no human safety information.

Name Approved application On FDA's compounding-risk page
BPC-157 None Yes
TB-500 (thymosin beta-4 fragment) None Yes
CJC-1295 None Yes
Ipamorelin None Yes (also 503B category 2)
MOTS-c None Yes
KPV None Yes
Epitalon None Yes
Selank, Semax None Yes
Thymosin alpha-1 None in the US Yes
GHK-Cu (injectable) None Yes
GHRP-2, GHRP-6 None 503B category 2
Kisspeptin-10 None 503A category 2
AOD-9604, DSIP, LL-37, PEG-MGF, dihexa None Yes

In July 2026 FDA's Pharmacy Compounding Advisory Committee reviewed seven of these. FDA's staff advised against all seven; the committee voted for six and against DSIP. A vote is advice, not an approval, and does not create an approved product either way. The detail, with sources, is on our peptide therapy page and our 503A category 2 page.

Reviewed July 2026 FDA staff Committee vote
BPC-157 Against 8–6 for
TB-500 Against 8–6 for
KPV Against 8–6 for
Semax Against 8–5 for
MOTS-c Against 7–5 for
Epitalon Against 7–5 for
Emideltide (DSIP) Against 6–7, rejected

Votes as reported by STAT, PharmExec and RAPS; FDA had posted no minutes when this table was compiled. CJC-1295, ipamorelin, selank and thymosin alpha-1 were not among the seven.

The pending step. On 14 October 2026 FDA sent the White House's Office of Information and Regulatory Affairs a notice titled "Interim Access Policy for Compounding Using Certain Peptides" (RIN 0910-ZD94, stage: notice). The OIRA review list still showed it as pending review on 20 October 2026, and its text has not been published, so which peptides it names and what it permits are unknown. Two things are certain from the title alone: it concerns compounding, not approval, and it cannot move any name in the table above into the census of approved ingredients. This page will be updated when FDA publishes it.

SS-31: the one research-market name that is now an approved drug

Elamipretide is the compound research sellers label SS-31. Drugs@FDA lists Forzinity (NDA 215244, Stealth BioTherapeutics) as approved on 19 September 2025 after a priority review — the newest row in the census. The Forzinity label (version effective 2025-12-10, read through openFDA on 2026-10-20) limits it to one use: improving muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. That is an accelerated approval, granted on knee-extensor strength — an intermediate endpoint — and the label says continued approval may depend on a confirmatory trial showing clinical benefit.

So "is SS-31 FDA-approved?" has a precise answer: elamipretide is approved, for a rare inherited mitochondrial disease, as one company's product. A vial sold as "SS-31" for research is not that product, carries none of its manufacturing controls, and no approval covers it.

What this list does not show

  • Approvals outside the US. Thymosin alpha-1, cerebrolysin, semax and selank are registered in other countries; this census is FDA only.
  • Every generic. Most marketed ingredients here also have generic applications; the table names reference brands.
  • Whether a compounded or research-market product contains what its label says. An approval covers the approved product made under its application, nothing else. How that is checked is on our peptide testing page.
  • Safety. Approval means FDA found benefits outweighed risks for a labelled use. What that leaves open is on our are peptides safe page.

GLP-1 drugs appear above as census rows only; their dosing, side effects and safety record are covered by GLP1 Ledger. Beginners' explanations of most molecules here are in Peptide Lexicon's compound index.

Sources and dates

  • Drugs@FDA via openFDA drugsfda endpoint, queried by brand name and active ingredient on 2026-10-06; dataset last_updated 2026-10-02. Kind of source: regulator database (tier 1).
  • 21 CFR 600.3(h)(6), eCFR, read 2026-10-06.
  • FDA, "Deemed to be a License" Provision of the BPCI Act, read 2026-10-06.
  • FDA, Certain bulk drug substances for use in compounding that may present significant safety risks, content current as of 2026-04-22, read 2026-10-06 and re-read 2026-10-20 (unchanged).
  • Drugs@FDA via openFDA, searched 2026-10-20 (dataset last_updated 2026-10-16): no application for CJC-1295, selank, MOTS-c or KPV; Forzinity NDA 215244 original approval 2025-09-19, priority review.
  • Forzinity (elamipretide) label, effective 2025-12-10, via openFDA drug label endpoint, read 2026-10-20.
  • OIRA, regulatory review list (reginfo.gov), RIN 0910-ZD94, received 2026-10-14, status "Pending Review", read 2026-10-20.
  • July 2026 Pharmacy Compounding Advisory Committee votes: STAT, PharmExec and RAPS reports, read 2026-10-03.

Frequently asked questions

How many peptides are FDA-approved?

FDA does not publish a count. Reading its approvals database on 6 October 2026, this census found 43 peptide active ingredients of 40 amino acids or fewer with at least one approved application, of which 37 still have a product listed as marketed. Published reviews give larger numbers, such as 'more than 80 peptide drugs', because they include insulins and other proteins, peptide antibiotics, and approvals outside the US.

Is BPC-157 FDA-approved?

No. There is no approved application for BPC-157. FDA lists it among bulk drug substances that may present significant safety risks when compounded, citing possible immunogenicity, peptide-related impurities and little or no safety information for the proposed routes. In July 2026 FDA's staff advised against adding it to the list of substances compounders may use; the advisory committee voted the other way. FDA had not acted on that vote when this page was written.

Is sermorelin FDA-approved?

It was. Sermorelin was approved as GEREF in 1990 (as a diagnostic test) and 1997 (as a treatment for children with growth hormone deficiency). Both applications are listed as discontinued, with FDA's finding that they were not withdrawn for safety or effectiveness reasons. That finding is why sermorelin can still be compounded.

Is tesamorelin FDA-approved?

Yes. Tesamorelin is approved as EGRIFTA, first in 2010, for reducing excess abdominal fat in adults with HIV and lipodystrophy. Its label states it is not indicated for weight loss. Because tesamorelin has 44 amino acids, FDA now treats it as a protein, and its application carries a biologics (BLA) number.

Is PT-141 FDA-approved?

Yes, under its generic name bremelanotide. Vyleesi was approved on 21 June 2019 for acquired low sexual desire in premenopausal women. Research-market products sold as 'PT-141' are not the approved product.

Is SS-31 (elamipretide) FDA-approved?

Yes, for one use. Elamipretide, the compound sold on the research market as SS-31, was approved as Forzinity (NDA 215244) on 19 September 2025, after a priority review. Its label indication is narrow: to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. The approval is an accelerated approval based on knee-extensor strength, an intermediate endpoint, and continued approval may depend on a confirmatory trial. Research-market 'SS-31' is not the approved product.

Is CJC-1295 FDA-approved?

No. Drugs@FDA lists no application for CJC-1295 (searched 20 October 2026). It is named on FDA's compounding-risk page among substances whose nominations for compounding use were withdrawn, and it was not one of the seven peptides FDA's advisory committee reviewed in July 2026.

Is selank FDA-approved?

No. There is no application for selank in Drugs@FDA (searched 20 October 2026). It is registered as a medicine in Russia, which is a different regulator's decision. FDA's compounding-risk page lists 'Selank acetate (TP-7)' among nominations that were withdrawn.

Is MOTS-c FDA-approved?

No. Drugs@FDA lists no application for MOTS-c (searched 20 October 2026). It was one of the seven peptides FDA's Pharmacy Compounding Advisory Committee reviewed in July 2026: FDA's staff advised against adding it to the list of substances compounders may use, and the committee voted 7 to 5 in favour. A committee vote is advice to FDA, not an approval.

Is KPV FDA-approved?

No. Drugs@FDA lists no application for KPV (searched 20 October 2026). At the July 2026 advisory committee review, FDA's staff advised against adding it to the compounding list and the committee voted 8 to 6 in favour; FDA had not acted on the vote when this page was updated.

Is FDA changing the rules on compounded peptides?

Possibly, but nothing has been published. On 14 October 2026 FDA sent the White House a notice titled 'Interim Access Policy for Compounding Using Certain Peptides' (RIN 0910-ZD94). On 20 October 2026 it was still listed as pending review, and which peptides it covers and what it allows are not public. Whatever it says, a compounding policy does not make any peptide an approved drug, and none of the names in the 'not approved' table below would join the census because of it.

Are GLP-1 drugs peptides?

Yes. Semaglutide, tirzepatide, liraglutide and exenatide are all peptides under 40 amino acids and appear in this census. Their safety, dosing and side effects are covered by GLP1 Ledger; this page lists their approval status only.